Bayer files riociguat for CTEPH and PAH in US and EU
This article was originally published in Scrip
Bayer has filed for approval in the US and EU for its oral soluble guanylate cyclase (sGC) stimulator riociguat for two forms of pulmonary hypertension. The company had planned the filings for the first half of 2013 following positive results in the two indications, chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary hypertension (PAH), both rare but life-threatening diseases. While there are approved therapies for PAH, the prognosis is poor. There are no currently approved drugs available for CTEPH.
You may also be interested in...
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.